Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
This is a leukemic cell line with an 8;21 chromosome translocation. This translocation juxtaposes the AML1 with ETO (or MTG8) gene, giving rise to the fusion gene AML1-ETO (also known as AML1-MTG or RUNX1-CBF2T1), hence the cells produce chimeric AML1-ETO protein. This protein down-regulates CEBPA mRNA, protein and DNA binding activity, which is crucial for the differentiation of granulocytes.
In proliferation assay the cells in culture showed response to interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), and granulocytemacrophage CSF (GM-CSF), but not to IL-1 or IL-5.
Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839
Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990
Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541
Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784
Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289
Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671
